<DOC>
	<DOC>NCT02830763</DOC>
	<brief_summary>This study is planning to evaluate the safety and clinical efficacy of medium-chain fatty acid capsules (food-grade CNT-02) in subjects with primary triglyceride deposit cardiomyovasculopathy (TGCV) and neutral lipid storage disease with myopathy (NLSD-M) associated with adipose triglyceride lipase (ATGL) genetic defects.</brief_summary>
	<brief_title>Clinical Study on the Safety of CNT-02 for TGCV and NLSD-M</brief_title>
	<detailed_description />
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Lipidoses</mesh_term>
	<mesh_term>Lipid Metabolism, Inborn Errors</mesh_term>
	<mesh_term>Ichthyosiform Erythroderma, Congenital</mesh_term>
	<criteria>1. Patients for whom ATGL gene deletion has been previously confirmed. 2. Patients who can take the investigational product orally. 3. Male and female who are at least 20 years old at the time of consent. 4. Patients who gave written informed consent. 1. Patients with diabetic ketoacidosis. 2. Patients with the possibility of diabetic ketoacidosis (patients with poorly controlled diabetes mellitus [HbA1c&gt;8.4%, NGSP]) 3. Patients with terminal malignancy. 4. Pregnant or lactating women. 5. Patients who do not consent to using contraception while participating in this study. 6. Patients allergic to MCT oil. 7. Patients participating in other clinical trial. 8. Otherwise, patients determined to be ineligible for this study by the investigator or subinvestigator.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>neutral lipid storage disease</keyword>
	<keyword>CNT-02</keyword>
	<keyword>primary triglyceride deposit cardiomyovasculopathy (TGCV)</keyword>
	<keyword>neutral lipid storage disease with myopathy (NLSD-M)</keyword>
</DOC>